- Top line revenues of $2.1B (+51%) driven by Avonex's $761M, Tecfidera's $506M, Tysabri's $441M and Rituxan & Gazyva's $297M.
- Revenue growth has accelerated for five consecutive quarters.
- The company recorded 100% of Tysabri revenues subsequent to its acquisition of the complete rights to the product in Q2.
- GAAP diluted EPS was $2.02 (+13%) and net income $480M (+12%).
- Full year guidance includes revenue growth of 26% - 28% and GAAP diluted EPS of $9.85 - $9.95.
- (NASDAQ:BIIB)